Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors. (Q53925655)

22 May 2018

title

Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors. (English)

1 reference

22 May 2018

author name string

Hsin-Yuan Wei

1

1 reference

22 May 2018

Guan-Ju Chen

2

1 reference

22 May 2018

Chih-Lun Chen

3

1 reference

22 May 2018

Thy-Hou Lin

4

1 reference

22 May 2018

publication date

12 May 2011

1 reference

22 May 2018

Journal of Molecular Modeling

published in

1 reference

22 May 2018

volume

18

1 reference

22 May 2018

issue

2

1 reference

22 May 2018

page(s)

675-692

1 reference

22 May 2018

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Alzheimer's disease. A firm base for drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

BACE1 is the major beta-secretase for generation of Abeta peptides by neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Conformationally biased P3 amide replacements of beta-secretase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Ensemble-docking approach on BACE-1: pharmacophore perception and guidelines for drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Discovery of a novel warhead against beta-secretase through fragment-based lead generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Comparative molecular field analysis and comparative molecular similarity indices analysis of hydroxyethylamine derivatives as selective human BACE-1 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

What's up and down with histone deacetylation and transcription?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Acetylation of histones and transcription-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Quantitative structure-activity relationship study of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Ras C-terminal processing enzymes--new drug targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

p21ras is modified by a farnesyl isoprenoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Cloning and expression of a cDNA encoding the alpha subunit of rat p21ras protein farnesyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

cDNA cloning and expression of the peptide-binding β subunit of rat p21rasfarnesyltransferase, the counterpart of yeast DPR1/RAM1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Ras farnesyltransferase: a new therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Farnesyltransferase inhibitors versus Ras inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Farnesyltransferase as a target for anticancer drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Imidazole-containing farnesyltransferase inhibitors: 3D quantitative structure-activity relationships and molecular docking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

On the use of some multivariate statistical methods in pharmacological research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Design of potent inhibitors of human beta-secretase. Part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Design of potent inhibitors of human beta-secretase. Part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

New-generation amber united-atom force field

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

Spouse caregivers of Alzheimer patients: problem responses to caregiver burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00894-011-1094-4

21 January 2018

1 reference

12 December 2020

Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques

1 reference

12 December 2020

Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

1 reference

12 December 2020

Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A

1 reference

12 December 2020

ras oncogenes in human cancer: a review

1 reference

12 December 2020

[Inhibitors of Ras farnesylation: tomorrow's anticancer agents?]

1 reference

12 December 2020

3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues

1 reference

12 December 2020

Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors

1 reference

12 December 2020

Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus

1 reference

12 December 2020

10.1007/S00894-011-1094-4

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018